Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,309 shares of the biopharmaceutical company’s stock after selling 1,498 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Gilead Sciences were worth $730,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after purchasing an additional 2,727,063 shares in the last quarter. Parnassus Investments CA increased its stake in Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after purchasing an additional 4,556,901 shares in the last quarter. APG Asset Management N.V. increased its stake in Gilead Sciences by 16.7% in the 1st quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock valued at $402,319,000 after purchasing an additional 849,741 shares in the last quarter. AQR Capital Management LLC increased its stake in Gilead Sciences by 25.7% in the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after purchasing an additional 1,066,172 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in Gilead Sciences by 6.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 4,706,832 shares of the biopharmaceutical company’s stock valued at $333,150,000 after purchasing an additional 302,787 shares in the last quarter. 73.88% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/checchi-capital-advisers-llc-trims-holdings-in-gilead-sciences-inc-gild.html.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares in the company, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders sold a total of 446,819 shares of company stock worth $36,338,919 over the last quarter. Company insiders own 1.30% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 77.88 on Friday. The firm has a market capitalization of $101.71 billion, a P/E ratio of 8.46 and a beta of 1.14. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The stock has a 50 day moving average of $82.38 and a 200-day moving average of $72.98.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the business posted $2.75 earnings per share. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.79 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.67%. Gilead Sciences’s payout ratio is currently 22.58%.

Several equities analysts have weighed in on the company. Jefferies Group LLC reissued a “hold” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 11th. Leerink Swann raised their price target on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research report on Thursday, October 19th. BMO Capital Markets restated an “outperform” rating and set a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Finally, Robert W. Baird restated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average price target of $85.64.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply